Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist.
about
Population Exposure-Response Modeling Supported Selection of Naloxegol Doses in Phase 3 Studies in Patients with Opioid Induced Constipation.Pharmacometric Modeling of Naloxegol Efficacy and Safety: Impact on Dose and Label.Effects of naloxegol on whole gut transit in opioid-naïve healthy subjects receiving codeine: A randomized, controlled trial.
P2860
Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Clinical Pharmacokinetics and ...... µ-Opioid Receptor Antagonist.
@en
Clinical Pharmacokinetics and ...... µ-Opioid Receptor Antagonist.
@nl
type
label
Clinical Pharmacokinetics and ...... µ-Opioid Receptor Antagonist.
@en
Clinical Pharmacokinetics and ...... µ-Opioid Receptor Antagonist.
@nl
prefLabel
Clinical Pharmacokinetics and ...... µ-Opioid Receptor Antagonist.
@en
Clinical Pharmacokinetics and ...... µ-Opioid Receptor Antagonist.
@nl
P2093
P2860
P1476
Clinical Pharmacokinetics and ...... g µ-Opioid Receptor Antagonist
@en
P2093
Diansong Zhou
Eike Floettmann
Hongmei Xu
Nidal Al-Huniti
P2860
P2888
P304
P356
10.1007/S40262-016-0479-Z
P50
P577
2017-06-01T00:00:00Z